HMPL-689 for Lymphoma

Phase 1

Waitlist Available

Led By Nilanjan Ghosh, MD

Research Sponsored by Hutchison Medipharma Limited

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from cycle 1 day 1 30 min pre-dose until cycle 2 day 1 30 min pre dose (escalation) from cycle 1 day 1 30 min pre-dose to cycle 5 day 1 pre-dose 30 min (expansion) (cycle is 28 days)

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new drug, HMPL-689, to see if it is safe and effective in treating patients with relapsed or refractory lymphomas.

Who is the study for?

This trial is for patients with certain types of lymphoma that have relapsed or are not responding to standard treatments. Participants should be in relatively good physical condition (ECOG status 0 or 1) and expected to live more than 24 weeks. They must not have severe organ dysfunction, recent major surgery, heart issues like congestive heart failure, a history of significant liver disease, or any other condition that could interfere with the study.

What is being tested?

The trial is testing HMPL-689's safety and how it's processed by the body in those with specific lymphomas that haven't responded well to other treatments. It's an open-label study where everyone knows what treatment they're getting, starting with small doses that increase over time.

What are the potential side effects?

While specific side effects for HMPL-689 aren't listed here, common ones for cancer drugs include nausea, fatigue, risk of infection due to low blood cell counts, liver problems which might show up as yellowing skin or eyes (jaundice), and potential heart rhythm issues.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from cycle 1 day 1 30 min pre-dose until cycle 2 day 1 30 min pre dose (escalation) from cycle 1 day 1 30 min pre-dose to cycle 5 day 1 pre-dose 30 min (expansion) (cycle is 28 days)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from cycle 1 day 1 30 min pre-dose until cycle 2 day 1 30 min pre dose (escalation) from cycle 1 day 1 30 min pre-dose to cycle 5 day 1 pre-dose 30 min (expansion) (cycle is 28 days)

This trial's timeline: 3 weeks for screening, Varies for treatment, and from cycle 1 day 1 30 min pre-dose until cycle 2 day 1 30 min pre dose (escalation) from cycle 1 day 1 30 min pre-dose to cycle 5 day 1 pre-dose 30 min (expansion) (cycle is 28 days) for reporting.